Akari Therapeutics (NASDAQ:AKTX – Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Monday, August 18th. Analysts expect Akari Therapeutics to post earnings of ($0.12) per share for the quarter.
Akari Therapeutics Stock Performance
Shares of NASDAQ AKTX opened at $1.01 on Friday. Akari Therapeutics has a twelve month low of $0.85 and a twelve month high of $4.22. The stock’s 50 day moving average price is $1.11 and its 200-day moving average price is $1.17.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on AKTX shares. Maxim Group began coverage on shares of Akari Therapeutics in a research report on Friday, July 18th. They issued a “buy” rating and a $5.00 target price for the company. Wall Street Zen started coverage on Akari Therapeutics in a research note on Wednesday, May 21st. They issued a “sell” rating on the stock.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Further Reading
- Five stocks we like better than Akari Therapeutics
- There Are Different Types of Stock To Invest In
- 3 Restaurant Stocks That Will Outperform in Q3 and Q4
- A Deeper Look at Bid-Ask Spreads
- The Midstream Energy Play That Keeps Powering Higher
- What is the Nikkei 225 index?
- Ethereum Near All-Time High: 3 Stocks Stacking ETH in Treasuries
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
